株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

世界の造血幹細胞移植(HSCT)市場:2017〜2021年

Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 560883
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
世界の造血幹細胞移植(HSCT)市場:2017〜2021年 Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2017-2021
出版日: 2017年09月27日 ページ情報: 英文 88 Pages
概要

造血幹細胞移植は、臍帯血を使用して最も広く用いられる幹細胞治療です。血液関連の疾患、神経変性疾患、心臓病、糖尿病など様々な疾患を治療するために造血幹細胞の様々な入手源を発見すべく研究が進められています。世界の造血幹細胞移植(HSCT)市場は2017〜2021年にかけCAGR5.75%で拡大すると予測されています。

当レポートでは、世界の造血幹細胞移植(HSCT)市場について調査し、市場の動向と治療用途別、移植別、地域別動向、競合動向、および市場に参入する主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 調査方法

第4章 イントロダクション

第5章 造血幹細胞移植(HSCT):概要

  • 造血幹細胞移植
  • 造血細胞の入手源
  • 移植の種類
  • 手技

第6章 パイプライン

第7章 市況

  • 市場概要
  • ファイブフォース分析

第8章 治療用途別市場セグメンテーション

第9章 移植別市場セグメンテーション

  • 自家HSCT
  • 同種HSCT

第10章 地域別セグメンテーション

  • 欧州・中東・アフリカ
  • 南北アメリカ
  • アジア太平洋地域

第11章 意思決定の枠組み

第12章 促進因子と課題

第13章 市場動向

  • 個別化医療の需要拡大
  • 罹患率と死亡率の減少
  • 臍帯血バンキングの動向
  • RIC治療計画への注力

第14章 ベンダー環境

  • 競合シナリオ

第15章 主要ベンダー分析

  • AllCells
  • Lonza
  • Merck
  • Sanofi
  • その他の注目すべきベンダー

第16章 付録

図表

図表
  • Exhibit 01: Developments in stem cell research
  • Exhibit 02: Global HSCT market snapshot
  • Exhibit 03: History of HSCT
  • Exhibit 04: HSCT sources
  • Exhibit 05: Types of transplant
  • Exhibit 06: Pipeline snapshot based on vendors
  • Exhibit 07: Pipeline snapshot based on type of intervention
  • Exhibit 08: Pipeline snapshot based on different-phases
  • Exhibit 09: Pipeline landscape
  • Exhibit 10: Purpose of trial
  • Exhibit 11: Global HSCT market snapshot 2016
  • Exhibit 12: Global HSCT market 2016-2021 ($ millions)
  • Exhibit 13: Opportunity analysis in global HSCT market
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Global HSCT market segmentation by therapeutic application
  • Exhibit 16: Global HSCT market share by therapeutic application
  • Exhibit 17: HSCT for other diseases
  • Exhibit 18: Global HSCT market segmentation by transplant type
  • Exhibit 19: Global HSCT market share by transplant type 2016
  • Exhibit 20: Global autologous HSCT market 2016-2021 ($ millions)
  • Exhibit 21: Opportunity analysis of global autologous HSCT market
  • Exhibit 22: Global allogenic HSCT market 2016-2021 ($ millions)
  • Exhibit 23: Opportunity analysis of global allogeneic HSCT market
  • Exhibit 24: Global HSCT market by geography 2016 and 2021
  • Exhibit 25: Global HSCT market revenue by geography 2016-2021 ($ millions)
  • Exhibit 26: Global HSCT market by geography 2016-2021 (%)
  • Exhibit 27: Market scenario in EMEA
  • Exhibit 28: HSCT market in EMEA 2016-2021 ($ millions)
  • Exhibit 29: Market scenario in Americas
  • Exhibit 30: HSCT market in Americas 2016-2021 ($ millions)
  • Exhibit 31: Market scenario in APAC
  • Exhibit 32: HSCT market in APAC 2016-2021 ($ millions)
  • Exhibit 33: Snapshot of transplant scenario from 1984-2007
  • Exhibit 34: Funding for stem cell research 2013-2018
  • Exhibit 35: Details of European Commission funding
  • Exhibit 36: Long-term complications associated with HSCT
  • Exhibit 37: Symptoms of GvHD
  • Exhibit 38: Risk of mortality in age-matched general population and HSCT patient with two years after allogenic transplant
  • Exhibit 39: Benefits of using RIC
  • Exhibit 40: Competitive structure analysis of global HSCT market 2016
  • Exhibit 41: AllCells: Key highlights
  • Exhibit 42: AllCells: Strength assessment
  • Exhibit 43: AllCells: Strategy assessment
  • Exhibit 44: AllCells: Opportunity assessment
  • Exhibit 45: Lonza: Key highlights
  • Exhibit 46: Lonza: Strength assessment
  • Exhibit 47: Lonza: Strategy assessment
  • Exhibit 48: Lonza: Opportunity assessment
  • Exhibit 49: Merck: Key highlights
  • Exhibit 50: Merck: Strength assessment
  • Exhibit 51: Merck: Strategy assessment
  • Exhibit 52: Merck: Opportunity assessment
  • Exhibit 53: Sanofi: Key highlights
  • Exhibit 54: Sanofi: Strength assessment
  • Exhibit 55: Sanofi: Strategy assessment
  • Exhibit 56: Sanofi: Opportunity assessment
目次
Product Code: IRTNTR14625

About Hematopoietic Stem Cells Transplantation (HSCT)

HSCT is the most widely used stem-cell therapy, where blood from umbilical cord is used. Research is being undertaken to discover various sources (such as cord blood cells, bone marrow, and peripheral blood cells) of hematopoietic stem cells to treat various disorders like hematological malignancies, blood related disorders (leukemia and lymphoma), neurodegenerative diseases and conditions such as heart disease, diabetes, and other conditions.

Stem-cell therapy has become controversial after developments in isolating and culturing of embryonic stem cells. Somatic cell nuclear transfer is the technique used in embryonic stem cell research to create stem cells and induced pluripotent stem cells. This controversy is related to abortion policies and human cloning. However, the changing regulatory landscape in countries like the US and Japan may help to accelerate the clinical trials.

Technavio's analysts forecast the global hematopoietic stem cells transplantation (HSCT) market to grow at a CAGR of 5.75% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global hematopoietic stem cells transplantation (HSCT) market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of hematopoietic stem cells transplantation (HSCT).

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Hematopoietic Stem Cells Transplantation (HSCT) Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AllCells
  • Lonza
  • Merck
  • Sanofi

Other Prominent Vendors

  • Athersys
  • Beike Biotechnology
  • BioTime
  • bluebird bio
  • Caladrius
  • Cellular Biomedicine Group
  • Cellular Dynamics International (a subsidiary of Fujifilm)
  • Cesca Therapeutics
  • CHA Biotech
  • CORESTEM
  • Gamida Cell
  • Global Stem Cells Group
  • Hemostemix
  • Histocell
  • Mesoblast
  • TiGenix
  • Translational Biosciences (a subsidiary of Medistem Panama)

Market driver

  • Rising number of HSCT
  • For a full, detailed list, view our report

Market challenge

  • High cost of HSCT
  • For a full, detailed list, view our report

Market trend

  • Growing demand for personalized medicine
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: HSCT: An overview

  • Hematopoietic stem cell transplantation
  • Source of hematopoietic cells
  • Types of transplant
  • The HSCT procedure

PART 06: Pipeline

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by therapeutic application

  • AML
  • ALL
  • HL
  • NHL
  • CML
  • MM
  • Others

PART 09: Market segmentation by transplant

  • Global autologous HSCT market
  • Global allogenic HSCT market

PART 10: Geographical segmentation

  • HSCT market in EMEA
  • HSCT market in Americas
  • HSCT market in APAC

PART 11: Decision framework

PART 12: Drivers and challenges

  • Market drivers
  • Market challenges

PART 13: Market trends

  • Growing demand for personalized medicine
  • Decreasing morbidity and mortality rate
  • Advent of cord blood banking
  • Increasing focus in RIC regimen

PART 14: Vendor landscape

  • Competitive scenario

PART 15: Key vendor analysis

  • AllCells
  • Lonza
  • Merck
  • Sanofi
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations
Back to Top